Abstract:Objectives: To analyze the incidence, blood lipid levels and cardiovascular disease of familial hypercholesterolemia (FH) in dyslipidemia patients receiving lipid-lowing therapy from the DYSIS-China. Methods: Dyslipidemia International Study-China (DYSIS-China) database was re-analyzed according to the criteria of "Chinese guidelines for prevention and treatment of dyslipidemia in adults-2016 version". DYSIS-China database included 25 317 dyslipidemia out-patients who received at least one lipid-lowering drug for at least three months. All the patients were divided into three groups: unlikely HF, possible FH and definite FH according to the Dutch Lipid Clinic Network diagnostic criteria. Age, gender, lipids levels, drug use and complications were compared among the three groups. Factors were compared between Possible FH group and definite FH group in terms of age stratification. Results: A total of 23 973 patients with dyslipidemia were included. The average age was (64.8±9.9) years, 11 757 patients were females (49.0%). The proportion of unlikely FH in the total population was 20 561 (85.7%), possible FH was 3294 (13.7%), and the definite FH was 118(0.5%). Patients in the definite FH group (58.3±8.5 years) was younger than in unlikely HF(65.3±9.8 years) and possible FH(61.8±9.9 years) group. LDL-C ((5.6±1.9) mmol/L) levels were significantly higher in definite FH group than in unlikely HF ((2.5±0.9) mmol/L) and possible FH ((4.3±1.0) mmol/L) group. TC ((7.4±1.8) mmol/L) levels were also significantly higher in definite FH group than in unlikely HF ((4.3±1.0) mmol/L) and possible FH ((6.0±1.0) mmol/L) group. Percent of female sex, sedentary lifestyle and systolic blood pressure value were significantly higher in definite FH group than in other two groups (all P<0.05). Statin use was similar among the 3 groups. Prevalence of ischemic cardiomyopathy (70(59.3%)) was significantly higher in the definite FH group than in unlikely FH group7519 (36.6%) and possible FH group1149 (34.9%). The rate of hypertension (82 (69.5%)) was also significantly higher in the definite FH group than in unlikely FH group (2 063 (62.6%) and in possible FH group (13 928 (67.7%)). The possible FH group had the highest proportion of patients aged 55-64 years (1 146 (34.8%)), and the prevalence of hypertension 358 (76.8%), diabetes 189 (40.6%), ischemic heart disease 186 (39.9%), cerebrovascular disease 149 (32.0%) and heart failure 28 (6.0%) was the highest in patients over 75 years old. The definite FH group had the highest proportion of patients aged 55-64 years (49 (41.52%)), and the prevalence of ischemic heart disease (70 (59.3%)) was the highest in patients aged 45-54 years old group, there was no significant difference in the prevalence of diabetes,hypertension,heart failure,peripheral artery disease and cerebrovascular disease among different age groups. Conclusion: The detection rate of FH in Chinese patients with dyslipidemia is not low, the blood lipid level is poorly controlled, and the risk of cardiovascular disease is high in Chinses FH patients.

Risk Factors Associated with Atherogenic Dyslipidemia in the Presence of Optimal Statin Therapy.

Achievement of Low-Density Lipoprotein Cholesterol Targets in Chinese Patients with Atherosclerotic Cardiovascular Disease after Receiving Statins and Ezetimibe

Higher prevalence of elevated LDL-C than non-HDL-C and low statin treatment rate in elderly community-dwelling Chinese with high cardiovascular risk

Contemporary Management And Attainment Of Cholesterol Targets For Patients With Dyslipidemia In China

Lipid goal attainment in post-acute coronary syndrome patients in China: Results from the 6-month real-world dyslipidemia international study II

Persistent Dyslipidemia in Chinese Patients Treated with Lipid-Lowering Drugs: Interim Results of the Dyslipidaemia International Study (dysis) China

Current Status and Time Trends of Lipid and Use of Statins among Older Adults in China-real World Data from Primary Community Health Institutions.

VARIABILITY IN PLASMA LIPIDS BETWEEN INTENSIVE STATINS THERAPY AND CONVENTIONAL DOSE STATINS COMBINED WITH EZETIMIBE THERAPY IN PATIENTS WITH CORONARY ATHEROSCLEROSIS DISEASE

[Status of Cholesterol Goal Attainment for the Primary and Secondary Prevention of Atherosclerotic Cardiovascular Disease in Dyslipidemia Patients Receiving Lipid-Lowering Therapy: DYSIS-China Subgroup Analysis].

Factors Influencing Low-Density Lipoprotein Cholesterol Target Achievement in Primary Care - Results from DYSIS China.

The Gender Differences In Baseline Characteristics And Statin Intervention Among Outpatients With Coronary Heart Disease In China: The China Cholesterol Education Program

The second multi-center survey of dyslipidemia management in China: goal attainment rate and related factors]

[Cut Offs and Risk Stratification of Dyslipidemia in Chinese Adults].

Re-analysis of DYSIS-China Cross-Sectional Survey According to " Chinese Guidelines for the Prevention and Treatment of Dyslipidemia in Adults (2016 Revision)"

LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China: Subgroup analysis of the dyslipidemia international study of China (DYSIS-China).

Association Between Alcohol Intake, Overweight, and Serum Lipid Levels and the Risk Analysis Associated with the Development of Dyslipidemia

[Cross Sectional Study of Familial Hypercholesterolemia in Dyslipidemia Patients Receiving Lipid-Lowering Therapy: DYSIS-China Subgroup Analysis].

Uncontrolled Hyperlipidemia in Chinese Patients Who Experienced Acute Coronary Syndrome: an Observational Study

Trends in prescribing rate of statins at discharge and modifiable factors in patients with atherosclerotic cardiovascular disease

LDL-cholesterol Goal Attainment under Persistent Lipid-Lowering Therapy in Northeast China

Risk and effect modifiers for poor glycemic control among the chinese diabetic adults on statin therapy: the kailuan study